Does the pause apply to private employers in Texas?

No. The order applies to Texas state agencies and public universities, including their academic medical centers. Private employers remain under federal H-1B rules and timelines. That said, collaborations with public campuses may still face delays if key work relies on state-affiliated labs, clinics, or shared research infrastructure subject to the pause.

How long will the Texas pause on new H-1B petitions last?

The directive pauses new H-1B petitions at state agencies and public universities through May 31, 2027, unless cleared by the Texas Workforce Commission on a case-by-case basis. Institutions should expect longer hiring cycles, more documentation, and potential start date shifts while seeking TWC approval or exploring alternative staffing plans.

What roles are most at risk from this action?

Faculty hires in engineering, computer science, and life sciences, plus clinicians and research staff at academic medical centers, face the most disruption. Projects that require specialized skills on fixed grant or trial timelines are particularly exposed, since onboarding delays can push milestone dates and affect funding or partnership deliverables.

What should investors monitor over the next quarter?

Watch for hiring freezes, delayed offer letters, or extended start dates at public universities and teaching hospitals. Track grant no-cost extensions, sponsored research updates, trial site activation timelines, and reported clinic throughput. Vendor guidance tied to Texas public systems can also signal procurement slowdowns linked to staffing and TWC approval timing.

Law and Government

January 28: Texas H-1B Freeze Puts Universities and Hospitals on Hold

ByHuzaifa Zahoor January 28, 2026January 28, 2026

The Texas H-1B visa freeze is now in effect, pausing new petitions at state agencies and public universities until May 31, 2027 unless approved by the Texas Workforce Commission. Gov. Greg Abbott’s order tightens hiring for professors, researchers, and clinicians, with ripple effects for labs and hospitals tied to public institutions. We outline what is paused, who needs approvals, and how this could slow research output, delay clinical staffing, and complicate biotech partnerships that depend on Texas-based academic capacity.